Why the study?
The role of myocardial revascularization by PCI or CABG in heart failure patients with coronary artery disease remains controversial.
Does myocardial revascularization (PCI or CABG) improve outcomes in heart failure patients with coronary artery disease compared to guideline-directed medical therapy?
Does myocardial revascularization (PCI or CABG) improve outcomes in heart failure patients with coronary artery disease compared to guideline-directed medical therapy?
This expert consensus statement recommends that revascularization in HF with CAD should be reserved for patients with persistent angina despite optimal GDMT, with decisions guided by a multidisciplinary heart team.
Answers are grounded in this paper and cite their sources.
Requires heart team personalization of revascularization in HF-CAD; extends prior data by incorporating modern GDMT effects on outcomes.
The role of myocardial revascularization in HF patients with coronary artery disease by either percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) is controversial. For patients with HFrEF, prior to the advances in pharmacological heart failure therapy over the last 10 years, evidence suggests a modest, long-term benefit of CABG over guideline-recommended medical therapy. In the era of modern medical therapy, revascularization had no benefit in HFrEF. Whether a patient with HF and CAD should be advised to have revascularization and, if so, which procedure remains unclear and should be discussed by the heart team given the limited and conflicting evidence. Evidence for viability or ischaemia-guided selection strategies is controversial. In all cases with HF, establishing and optimizing GDMT and device therapy is required. When HF symptoms dominate despite GDMT, additional invasive procedures are not indicated. When angina persists despite GDMT and device therapy, revascularization should be considered. The choice of revascularization procedure should be discussed in the heart team, considering symptoms and ischemic burden, surgical risk, coronary complexity and the applicable HF treatment.
No takes yet. Share an insight, caveat, or question.
Haring et al. (2026) conducted a review in Heart failure with coronary artery disease. Myocardial revascularization (PCI or CABG) vs. Guideline-directed medical therapy was evaluated. Myocardial revascularization in heart failure with coronary artery disease lacks proven benefit over modern medical therapy unless angina persists, requiring individualized heart team discussion.
Synapse has enriched 10 related papers. Consider them for comparative context: